化合物U-104 T2017

Product Introduction
Bioactivity


英文名: U-104

描述: U-104 (NSC-213841) 是 CA IX 和 CA XII 碳酸酐酶 (CA) 抑制剂，其 Ki 分别为 45.1 nM 和 4.5 nM。小鼠模型中，它能够表现出明显的抑制肿瘤生长的作用。

激酶实验: Kinase assay: Calu-6 cells are cultured in MEM containing 10% fetal bovine serum and 1% penicillin/streptomycin and plated 1 day before the start of the experiment at 1 × 104 cells per well in a 384-well plate. Proteasome activity is assessed by monitoring hydrolysis of the chymotrypsin-like substrate Suc-LLVY-aminoluciferin in the presence of luciferase using the Proteasome-Glo assay reagents according to the manufacturer's instructions. Luminescence is measured using a LEADseeker instrument.

体外活性: 在转移性MDA-MB-231LM2-4Luc +细胞中,U-104（<50 μM）以剂量依赖性方式显着降低细胞迁移。

体内活性: 在4T1实验用转移小鼠模型中,U-104（19 mg/kg）可抑制转移形成.植入MDA-MB-231 LM2-4Luc+细胞的小鼠中, U-104（38 mg/kg）抑制原代肿瘤的生长并减少癌症干细胞数量.植入4T1细胞的Balb/c小鼠中,口服给药U-104（5 mg/mL）减缓了肿瘤生长速度.

存储条件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

溶解度: DMSO : 30.9 mg/mL (100 mM)


关键字: LM2-4 | NSC213841 | CAIX | CAI | CAXII | U-104 | exosome | SLC-0111 | SLC0111 | Carbonate dehydratase | NSC 213841 | Carbonic Anhydrase | U104 | inhibit | SLC 0111 | 4T1 | U 104 | Inhibitor | CAII | MST104 | MST 104

相关产品: hCAIX/XII-IN-8 | Orthanilamide | Polmacoxib | Dichlorphenamide | CAIX Inhibitor S4 | Brinzolamide | EMD57033 | Sultiame | 6-Hydroxycoumarin | Methazolamide

相关库: Anti-Aging Compound Library | Drug Repurposing Compound Library | Glycometabolism Compound Library | Anti-Cancer Compound Library | Anti-Cancer Drug Library | Anti-Cancer Clinical Compound Library | Inhibitor Library | Anti-Cancer Active Compound Library | NO PAINS Compound Library | Covalent Inhibitor Library

化合物U-104 T2017信息由TargetMol中国为您提供，如您想了解更多关于化合物U-104 T2017报价、型号、参数等信息，欢迎来电或留言咨询。

注：该产品未在中华人民共和国食品药品监督管理部门申请医疗器械注册和备案，不可用于临床诊断或治疗等相关用途